Compass Therapeutics: A Buy Rating on Promising Pipeline and Solid Financials
Buy Rating Affirmed for Compass Therapeutics on Strong Financials and Promising Clinical Trials
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics t
Compass Therapeutics Q1 EPS $(0.08) Beats $(0.11) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 33.33 percent decrease over losses of
Compass Therapeutics | 10-Q: Quarterly report
Press Release: Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update -- Received FDA Fast Track Designation for the investigation of CTX-009 in combination with pa
Top Premarket Gainers
XBP Europe Holding (XBP) shares surged 70% Monday premarket following a 2.8% drop in the previous session. Perficient (PRFT) shares soared 52% after the company said it agreed to a $3 billion takeover
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
Compass Therapeutics' CTX-009 Gains FDA Fast Track Status
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination With Paclitaxel for the Treatment of Patients With Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study Top-line data
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics with a Buy and maintains $10 price target.
HC Wainwright & Co. : The Compass Therapeutics (CMPX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : The Compass Therapeutics (CMPX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Compass Therapeutics (CMPX) said Tuesday it dosed its first patient in its phase 1 trial of CTX-8371, a potential cancer treatment. CTX-8371 is a bispecific checkpoint inhibitor. The study includes f
Compass Therapeutics Announces First Patient Dosed In Phase 1 Study Of CTX-8371 In Patients With Solid Tumors
Compass Therapeutics Announces First Patient Dosed In Phase 1 Study Of CTX-8371 In Patients With Solid Tumors
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics
Buy Rating on Compass Therapeutics for Breakthrough in Resistant Tumor Treatment
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Compass Therapeutics, Inc. (Nasdaq: CMPX) today presents a poster on the combination of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471, on anti-tumor activity in preclinical models at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, California on April 9.
No Data